Table 2 Univariate and multivariate analysis of the prognostic value of miR-25 and miR-142 in PFS
Variables | Number of patients | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
HR (95%CI) | P value | HR (95%CI) | P value | ||
Age | 380 | 1.015 (1.002–1.027) | 0.024 | 1.012 (0.999–1.025) | 0.062 |
Stage |  |  | < 0.001 |  | < 0.001 |
 Early | 51 | 1 |  | 1 |  |
 Late | 329 | 6.894 (3.400–13.981) | 5.861 (2.873–11.954) | ||
Grade | Â | Â | 0.384 | Â | / |
 Low | 74 | 1 |  | / |  |
 High | 281 | 0.871 (0.639–1.188) |  | / |  |
 NA | 25 | / |  | / |  |
Debulking |  |  | 0.002 |  | < 0.001 |
 Optimal | 290 | 1 |  | 1 |  |
 Suboptimal | 88 | 2.115 (1.594–2.807) |  | 1.712 (1.278–2.292) |  |
 Inoperable | 2 | / |  |  |  |
Treatment | Â | Â | 0.009 | Â | 0.003 |
 Standard | 181 | 1 |  | 1 |  |
 Standard+Bevacizumab | 199 | 0.711 (0.550–0.918) |  | 0.676 (0.521–0.876) |  |
miR-25 expression | Â | Â | 0.006 | Â | 0.020 |
 Low | 341 | 1 |  | 1 |  |
 High | 39 | 0.501 (0.306–0.822) |  | 0.554 (0.338–0.910) |  |
miR-142 expression | Â | Â | 0.747 | Â | / |
 Low | 99 | 1 |  | / |  |
 High | 281 | 1.050 (0.782–1.410) |  | / |  |